Urinary PCA3 score predicts prostate cancer multifocality - Abstract

Department of Medical Unit of Molecular Oncology and Transfer, Medical Faculty of Lyon 1, Lyon, France. Department of University of Lyon, Lyon, France; Institute of Functional Genomics of Lyon , Lyon, France.

The urinary PCA3 gene test has proved helpful for deciding whether to (re)biopsy to diagnose prostate cancer. We searched for pathological features that influence the shedding of PCA3 producing prostate cancer cells in urine after digital rectal examination.

Included in our study were 102 patients with an informative PCA3 score on the Progensa® PCA3 assay who underwent radical prostatectomy. Correlations were evaluated between PCA3 score and histopathological factors on prostatectomy, including tumor site in the prostate and the number of cancer foci.

PCA3 score significantly correlated with total tumor volume in prostatectomy specimens (p < 0.001) but not with prostatectomy Gleason score or pathological stage. PCA3 score positively correlated with apical and basal invasion, and with bilaterality and multifocality. On multivariate analysis multifocality was an independent factor influencing PCA3 score (p = 0.012).

Site in the prostate gland and the number of cancer foci may explain the observed PCA3 score variation in patients operated on for prostate cancer. The PCA3 test could be helpful in preoperatively selecting patients with unifocal and unilateral cancer who could benefit from active surveillance or focal therapy.

Written by:
Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A.   Are you the author?

Reference: J Urol. 2011 Feb 18. Epub ahead of print.
doi: 10.1016/j.juro.2010.11.072

PubMed Abstract
PMID: 21334023

UroToday.com Prostate Cancer Section

email news signup